{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016014","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.685172+00:00","generated_at":"2026-05-18T23:36:22.727687+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lipocine to host R&D event July 9, 2025 on LPCN 1154 for postpartum depression; Phase 3 data Q2 2026","bullets":["Virtual R&D investor event on July 9, 2025 at 11 AM ET to discuss LPCN 1154 (BRLIZIO) for postpartum depression (PPD).","Phase 3 registrational study recently initiated; top-line data expected in Q2 2026.","Event features Dr. Kristina Deligiannidis; includes clinical, regulatory, and development updates with Q&A.","LPCN 1154 is an oral brexanolone formulation targeting rapid symptom relief with 48-hour outpatient treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016014","json":"https://secwatch.observer/filing/0001641172-25-016014.json","markdown":"https://secwatch.observer/filing/0001641172-25-016014.md","text":"https://secwatch.observer/filing/0001641172-25-016014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225016014/0001641172-25-016014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225016014/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:36:22.727687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}